Back to mobile site

BMO Capital Reiterates Outperform Rating on Disc Medicine (IRON)

January 29, 2026 4:49 AM EST Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $120.00 price target on Disc Medicine (NASDAQ: IRON).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login